Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
暂无分享,去创建一个
Yasuo Arai | H. Ogura | Y. Arai | H. Sugimoto | Yoshiharu Yamanishi | Y. Yamanishi | Hachiro Sugimoto | Hiroo Ogura | Youichi Limura | Y. Limura
[1] J. Morris,et al. Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .
[2] H. Ogura,et al. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. , 2001, European journal of pharmacology.
[3] H. Ogura,et al. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. , 2000, Methods and findings in experimental and clinical pharmacology.
[4] A. R. Green,et al. Comparison of donepezil-, tacrine-, rivastigmine-and metrifonateinduced central and peripheral cholinergically mediated responses in the rat , 2000, Journal of psychopharmacology.
[5] Y. Kuriya,et al. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. , 2000, European journal of pharmacology.
[6] H. Ogura,et al. Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. , 2000, Methods and findings in experimental and clinical pharmacology.
[7] Y. Kuriya,et al. Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. , 1999, European journal of pharmacology.
[8] Y. Kuriya,et al. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. , 1999, European journal of pharmacology.
[9] R. Doody. Clinical benefits of a new piperidine-class AChE inhibitor , 1999, European Neuropsychopharmacology.
[10] R. Mohs,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.
[11] J. Pratt,et al. Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020 , 1998, Psychopharmacology.
[12] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[13] S. Tye,et al. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys , 1997, Psychopharmacology.
[14] Y. Mimori,et al. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor , 1997, Behavioural Brain Research.
[15] X. Tang,et al. Huperzine A, a novel promising acetylcholinesterase inhibitor , 1996, Neuroreport.
[16] D. Braida,et al. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. , 1996, European journal of pharmacology.
[17] E. Giacobini,et al. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex , 1996, Neuropharmacology.
[18] H. Sugimoto,et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. , 1995, Journal of medicinal chemistry.
[19] T. Sato,et al. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). , 1995, Biological & pharmaceutical bulletin.
[20] D. Knopman,et al. The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.
[21] K. Kawashima,et al. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.
[22] J. Blake,et al. Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase. , 1994, Journal of medicinal chemistry.
[23] A. Galli,et al. Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020. , 1994, European journal of pharmacology.
[24] G. Dawson,et al. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory , 1993, Behavioural Brain Research.
[25] A. Ohnishi,et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. , 1993, International journal of clinical pharmacology, therapy, and toxicology.
[26] H. Sugimoto,et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives. , 1992, Journal of medicinal chemistry.
[27] Martin R. Farlow,et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.
[28] C. J. Moore,et al. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties , 1992 .
[29] T Nakamura,et al. Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. , 1990, Journal of medicinal chemistry.
[30] M. Albert,et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.
[31] B. Davies,et al. HEPATOTOXICITY OF TETRAHYDROACRIDINE , 1988, The Lancet.
[32] A. Kling,et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.
[33] N. Sharpless,et al. PLASMA PHYSOSTIGMINE CONCENTRATIONS AFTER ORAL ADMINISTRATION , 1985, The Lancet.
[34] R. Whelpton,et al. PHYSOSTIGMINE CONCENTRATIONS AFTER ORAL DOSES , 1985, The Lancet.
[35] B. Reisberg,et al. Effects of naloxone in senile dementia: a double-blind trial. , 1983, The New England journal of medicine.
[36] D L Price,et al. Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.
[37] A. Wettstein,et al. No effect from double‐blind trial of physostigmine and lecithin in Alzheimer disease , 1983, Annals of neurology.
[38] R. Bartus,et al. The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.
[39] J. Coyle,et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.
[40] G. Marsh,et al. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. , 1981, Biological psychiatry.
[41] J. Ferguson,et al. Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia , 1981, British Journal of Psychiatry.
[42] M. Sugishita,et al. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. , 1979, Archives of neurology.
[43] E K Perry,et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.
[44] G. Blessed,et al. NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.
[45] P. Davies,et al. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.
[46] D M Bowen,et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. , 1976, Brain : a journal of neurology.
[47] Conn Nk,et al. Letter: Avirulent corynebacteria. , 1975 .
[48] K. Courtney,et al. A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.
[49] Shaw Fh,et al. The pharmacology of some new anti-cholinesterases. , 1953 .
[50] K. Partanen. MRI of Hippocampus in Incipient Alzheimer ' s Disease , 2003 .
[51] Y. Kuriya,et al. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. , 1999, Japanese journal of pharmacology.
[52] J. Morris,et al. Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .
[53] S H Ferris,et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.
[54] H. Ogura,et al. Inhibitory Action of E2020, a Novel Acetylcholinesterase Inhibitor, on Cholinesterase: Comparison with Other Inhibitors , 1990 .
[55] B. Davies,et al. Hepatotoxicity of tetrahydroaminoacridine. , 1988, Lancet.
[56] K. Davis,et al. Oral physostigmine treatment of patients with Alzheimer's disease. , 1985, The American journal of psychiatry.
[57] Memory enhancement with oral physostigmine in Alzheimer's disease. , 1983, The New England journal of medicine.
[58] J. Massoulie,et al. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. , 1982, Annual review of neuroscience.
[59] Ann Silver,et al. The biology of cholinesterases , 1974 .
[60] F. Shaw,et al. The pharmacology of some new anti-cholinesterases. , 1953, The Australian journal of experimental biology and medical science.
[61] A. Alzheimer. Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .